Cytochrome P450 2D6 and glutathione S‐transferase genotype in sudden infant death syndrome

The risk of sudden infant death syndrome (SIDS) has been linked with xenobiotic exposures, race and inheritance. Because cytochrome P450 2D6 (CYP2D6) and glutathione S‐transferases (GSTM1 and GSTT1) are genetically regulated, polymorphically distributed, and responsible for detoxification of many centrally acting exogenous and endogenous bioactive compounds, our objective was to determine whether the prevalences of deficiencies in CYP2D6, GSTM1, and GSTT1 differ in SIDS victims compared to healthy controls.

[1]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[2]  M. Relling,et al.  Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. , 1996, Pharmacogenetics.

[3]  F. Guengerich,et al.  Conjugation of carcinogens by 9 class glutathione S-transferases: mechanisms and relevance to variations in human risk , 1995 .

[4]  M. Spitz,et al.  Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. , 1995, Carcinogenesis.

[5]  A. Fryer,et al.  Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: interactions with GSTM1, CYP2D6 and smoking. , 1994, Carcinogenesis.

[6]  E. Mitchell,et al.  Observations on ethnic differences in SIDS mortality in New Zealand. , 1994, Early human development.

[7]  A. Hilder.  Ethnic differences in the sudden infant death syndrome: what we can learn from immigrants to the UK. , 1994, Early human development.

[8]  M. Relling,et al.  Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. , 1994, Human molecular genetics.

[9]  D. Bernstein,et al.  Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. , 1994, Carcinogenesis.

[10]  K. Husgafvel‐Pursiainen,et al.  Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. , 1994, Carcinogenesis.

[11]  G. Tucker,et al.  Clinical implications of genetic polymorphism in drug metabolism. , 1994, The Journal of pharmacy and pharmacology.

[12]  C. Pui,et al.  Thiopurine methyltransferase activity in American white subjects and black subjects , 1994, Clinical pharmacology and therapeutics.

[13]  Jack A. Taylor,et al.  Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. , 1993, Journal of the National Cancer Institute.

[14]  K. Nakachi,et al.  Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. , 1993, Cancer research.

[15]  L. Arendt-Nielsen,et al.  Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? , 1993, Pain.

[16]  N. Weiss,et al.  The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. , 1993, Cancer research.

[17]  M. Relling,et al.  Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. , 1993, The Journal of clinical investigation.

[18]  R. Clayton,et al.  The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas. , 1993, Carcinogenesis.

[19]  L. Bertilsson,et al.  Genetically variable metabolism of antidepressants and neuroleptic drugs in man. , 1993, Pharmacogenetics.

[20]  A. Lafuente,et al.  Human glutathione S-transferase mu (GST mu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. , 1993, Cancer letters.

[21]  M. Eichelbaum,et al.  Genetically determined differences in drug metabolism as a risk factor in drug toxicity. , 1992, Toxicology letters.

[22]  F. Perera,et al.  Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase mu. , 1992, Environmental health perspectives.

[23]  J. Daling,et al.  Sudden infant death syndrome in Washington State: why are Native American infants at greater risk than white infants? , 1992, The Journal of pediatrics.

[24]  J. Broome,et al.  The human glutathione S-transferases: comparison of isoenzyme expression in normal and astrocytoma brain. , 1992, Biochimica et biophysica acta.

[25]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[26]  C. Alm,et al.  Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. , 1992, Therapeutic drug monitoring.

[27]  M. Relling,et al.  Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. , 1991, Pharmacogenetics.

[28]  A. Kong,et al.  Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama. , 1991, Pharmacogenetics.

[29]  F. Gonzalez,et al.  A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. , 1991, Carcinogenesis.

[30]  A. Llerena,et al.  Polymorphic oxidation of debrisoquine in women with breast cancer. , 1991, Oncology.

[31]  D. Nebert.  Role of genetics and drug metabolism in human cancer risk. , 1991, Mutation research.

[32]  M. Relling,et al.  Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects , 1991, Clinical pharmacology and therapeutics.

[33]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[34]  M. Relling,et al.  Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin‐oxidation and N‐acetylation phenotypes in children , 1989, Clinical pharmacology and therapeutics.

[35]  D. Shannon,et al.  Familial occurrence of sudden infant death syndrome and apnea of infancy. , 1987, Pediatrics.

[36]  J. Daling,et al.  Infant mortality among subsequent siblings of infants who died of sudden infant death syndrome. , 1986, The Journal of pediatrics.

[37]  R. Pero,et al.  A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. , 1986, Carcinogenesis.

[38]  A. Kahn,et al.  Phenothiazine-induced sleep apneas in normal infants. , 1985, Pediatrics.

[39]  A. Kahn,et al.  Phenothiazines and sudden infant death syndrome. , 1982, Pediatrics.

[40]  A. Kahn,et al.  POSSIBLE ROLE OF PHENOTHIAZINES IN SUDDEN INFANT DEATH , 1979, The Lancet.

[41]  F. Guengerich.  Metabolism and genotoxicity of dihaloalkanes. , 1994, Advances in pharmacology.

[42]  B. Ketterer,et al.  Enzymology of cytosolic glutathione S-transferases. , 1994, Advances in pharmacology.

[43]  C. Smith,et al.  Genetic polymorphisms in xenobiotic metabolism. , 1994, European journal of cancer.

[44]  R. Morgenstern,et al.  Enzymology of microsomal glutathione S-transferase. , 1994, Advances in pharmacology.

[45]  J. Idle,et al.  Metabolic polymorphisms. , 1993, Pharmacology & therapeutics.

[46]  S. Tsuchida,et al.  Glutathione transferases and cancer. , 1992, Critical reviews in biochemistry and molecular biology.

[47]  Y. T. Chen,et al.  Cloning genes that encode drug-metabolizing enzymes: developmental pharmacology and teratology. , 1983, Progress in clinical and biological research.